|
End-of-day quote
Shanghai S.E.
17/08/2026
|
5-day change | 1st Jan Change | ||
| 3.930 CNY | +1.29% |
|
+4.80% | -1.26% |
Company Valuation: Guizhou Yibai Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 4,134 | 6,438 | 4,379 | 4,506 | 2,801 | 3,122 |
| Change | - | 55.75% | -31.98% | 2.89% | -37.83% | 11.44% |
| Enterprise Value (EV) 1 | 4,599 | 6,971 | 4,874 | 4,807 | 3,212 | 3,339 |
| Change | - | 51.58% | -30.08% | -1.38% | -33.17% | 3.95% |
| P/E | 18.1x | 26.4x | -10.3x | 43.4x | -8.86x | -9.48x |
| PBR | 1.23x | 1.84x | 1.44x | 1.47x | 1.12x | 1.43x |
| PEG | - | 4.02x | 0x | -0x | 0x | -2.12x |
| Capitalization / Revenue | 1.21x | 1.92x | 1.6x | 1.6x | 1.29x | 1.68x |
| EV / Revenue | 1.35x | 2.08x | 1.78x | 1.7x | 1.48x | 1.79x |
| EV / EBITDA | 7.57x | 12x | 12.3x | 13.2x | -42.8x | 219x |
| EV / EBIT | 9.85x | 16.1x | 21.8x | 28x | -12.4x | -22.5x |
| EV / FCF | 59.2x | 24.1x | -39.3x | 28.7x | 35.7x | 12.2x |
| FCF Yield | 1.69% | 4.14% | -2.54% | 3.49% | 2.8% | 8.23% |
| Dividend per Share 2 | 0.43 | - | - | 0.066 | - | - |
| Rate of return | 8.24% | - | - | 1.16% | - | - |
| EPS 2 | 0.289 | 0.308 | -0.539 | 0.131 | -0.402 | -0.42 |
| Distribution rate | 149% | - | - | 50.4% | - | - |
| Net sales 1 | 3,413 | 3,347 | 2,735 | 2,821 | 2,174 | 1,863 |
| EBITDA 1 | 607.6 | 580.7 | 395.1 | 363.4 | -75.06 | 15.24 |
| EBIT 1 | 466.7 | 433.1 | 223.1 | 171.8 | -259 | -148.7 |
| Net income 1 | 228.8 | 243.8 | -426.5 | 103.4 | -317.2 | -329.6 |
| Net Debt 1 | 465 | 532.5 | 494.6 | 300.7 | 410.9 | 217.1 |
| Reference price 2 | 5.220 | 8.130 | 5.530 | 5.690 | 3.560 | 3.980 |
| Nbr of stocks (in thousands) | 7,91,927 | 7,91,927 | 7,91,927 | 7,91,927 | 7,86,890 | 7,84,394 |
| Announcement Date | 22/04/21 | 22/04/22 | 27/04/23 | 18/04/24 | 25/04/25 | 22/04/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 45Cr | ||
| 33.76x | 12.18x | 24.85x | 0.59% | 1,05200Cr | ||
| 28.96x | - | - | 2.06% | 63TCr | ||
| 31.84x | 7.42x | 15.42x | 2.75% | 44TCr | ||
| 19.79x | 4.7x | 11.65x | 2.81% | 35TCr | ||
| 21.42x | 5.54x | 13.77x | 2.89% | 29TCr | ||
| 19.89x | 4.11x | 11.68x | 2.14% | 24TCr | ||
| 26.26x | 6.84x | 12.14x | 2.43% | 22TCr | ||
| 13.32x | 4.79x | 9.96x | 3.83% | 20TCr | ||
| -42.28x | 6.13x | 23.96x | 2.38% | 17TCr | ||
| Average | 17.00x | 6.46x | 15.43x | 2.43% | 35.96TCr | |
| Weighted average by Cap. | 24.17x | 8.04x | 17.73x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 600594 Stock
- Valuation Guizhou Yibai Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















